{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:56:07Z","timestamp":1793804167886,"version":"4.6.1"},"reference-count":331,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41581-024-00850-0","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T12:10:10Z","timestamp":1720008610000},"page":"672-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["The role of antibody glycosylation in autoimmune and alloimmune kidney diseases"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2637-4020","authenticated-orcid":false,"given":"Ana\u00efs","family":"Beyze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Larroque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moglie","family":"Le Quintrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"850_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","volume":"12","author":"GM Leone","year":"2023","unstructured":"Leone, G. M., Mangano, K., Petralia, M. C., Nicoletti, F. & Fagone, P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J. Clin. Med. 12, 1630 (2023).","journal-title":"J. Clin. Med."},{"key":"850_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","volume":"12","author":"T Lu","year":"2023","unstructured":"Lu, T., Zhang, J., Xu-Monette, Z. Y. & Young, K. H. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp. Hematol. Oncol. 12, 72 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"850_CR3","doi-asserted-by":"publisher","first-page":"175883592311872","DOI":"10.1177\/17588359231187201","volume":"15","author":"M Pegram","year":"2023","unstructured":"Pegram, M. et al. Evolving perspectives on the treatment of HR+\/HER2+ metastatic breast cancer. Ther. Adv. Med. Oncol. 15, 17588359231187201 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"850_CR4","doi-asserted-by":"publisher","first-page":"12383","DOI":"10.3390\/ijms241512383","volume":"24","author":"G Rizzetto","year":"2023","unstructured":"Rizzetto, G., De Simoni, E., Molinelli, E., Offidani, A. & Simonetti, O. Efficacy of pembrolizumab in advanced melanoma: a narrative review. Int. J. Mol. Sci. 24, 12383 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"850_CR5","doi-asserted-by":"publisher","first-page":"1215216","DOI":"10.3389\/fimmu.2023.1215216","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. & Murakhovskaya, I. Rituximab resistance in ITP and beyond. Front. Immunol. 14, 1215216 (2023).","journal-title":"Front. Immunol."},{"key":"850_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/17474086.2023.2246651","volume":"16","author":"S Yadav","year":"2023","unstructured":"Yadav, S. et al. Role of daratumumab in the frontline management of multiple myeloma: a narrative review. Expert Rev. Hematol. 16, 743\u2013760 (2023).","journal-title":"Expert Rev. Hematol."},{"key":"850_CR7","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder","year":"2010","unstructured":"Schroeder, H. W. & Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41\u201352 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"850_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/bj2710285","volume":"271","author":"MA Kerr","year":"1990","unstructured":"Kerr, M. A. The structure and function of human IgA. Biochem. J. 271, 285\u2013296 (1990).","journal-title":"Biochem. J."},{"key":"850_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/antib8040057","volume":"8","author":"P de Sousa-Pereira","year":"2019","unstructured":"de Sousa-Pereira, P. & Woof, J. M. IgA: structure, function, and developability. Antibodies 8, 57 (2019).","journal-title":"Antibodies"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/antib9040053","volume":"9","author":"BA Keyt","year":"2020","unstructured":"Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F. & Peterson, M. S. Structure, function, and therapeutic use of IgM antibodies. Antibodies 9, 53 (2020).","journal-title":"Antibodies"},{"key":"850_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/antib8010019","volume":"8","author":"BJ Sutton","year":"2019","unstructured":"Sutton, B. J., Davies, A. M., Bax, H. J. & Karagiannis, S. N. IgE antibodies: from structure to function and clinical translation. Antibodies 8, 19 (2019).","journal-title":"Antibodies"},{"key":"850_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).","journal-title":"Front. Immunol."},{"key":"850_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176\u2013189 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"850_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","volume":"25","author":"JN Arnold","year":"2007","unstructured":"Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21\u201350 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"850_CR15","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.molimm.2010.04.006","volume":"47","author":"GC Flynn","year":"2010","unstructured":"Flynn, G. C., Chen, X., Liu, Y. D., Shah, B. & Zhang, Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol. Immunol. 47, 2074\u20132082 (2010).","journal-title":"Mol. Immunol."},{"key":"850_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1021\/pr300887z","volume":"12","author":"MP Bakovi\u0107","year":"2013","unstructured":"Bakovi\u0107, M. P. et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J. Proteome Res. 12, 821\u2013831 (2013).","journal-title":"J. Proteome Res."},{"key":"850_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jim.2012.05.022","volume":"382","author":"KR Anumula","year":"2012","unstructured":"Anumula, K. R. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc. J. Immunol. Methods 382, 167\u2013176 (2012).","journal-title":"J. Immunol. Methods"},{"key":"850_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/0-387-25515-X_26","volume":"564","author":"R Jefferis","year":"2005","unstructured":"Jefferis, R. Glycosylation of natural and recombinant antibody molecules. Adv. Exp. Med. Biol. 564, 143\u2013148 (2005).","journal-title":"Adv. Exp. Med. Biol."},{"key":"850_CR19","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jaci.2022.10.035","volume":"151","author":"J Koers","year":"2023","unstructured":"Koers, J. et al. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J. Allergy Clin. Immunol. 151, 1646\u20131654 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"850_CR20","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1074\/mcp.M114.039537","volume":"13","author":"A Bondt","year":"2014","unstructured":"Bondt, A. et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol. Cell Proteom. 13, 3029\u20133039 (2014).","journal-title":"Mol. Cell Proteom."},{"key":"850_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck, L. H. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"850_CR22","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","volume":"100","author":"A Grupper","year":"2016","unstructured":"Grupper, A. et al. Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications. Transplantation 100, 2710\u20132716 (2016).","journal-title":"Transplantation"},{"key":"850_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3389\/fimmu.2019.01326","volume":"10","author":"P Passerini","year":"2019","unstructured":"Passerini, P., Malvica, S., Tripodi, F., Cerutti, R. & Messa, P. Membranous nephropathy (MN) recurrence after renal transplantation. Front. Immunol. 10, 1326 (2019).","journal-title":"Front. Immunol."},{"key":"850_CR24","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1093\/ndt\/gfq223","volume":"25","author":"G Moroni","year":"2010","unstructured":"Moroni, G. et al. Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN). Nephrol. Dial. Transpl. 25, 3408\u20133415 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"850_CR25","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","volume":"99","author":"D Zhu","year":"2002","unstructured":"Zhu, D. et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99, 2562\u20132568 (2002).","journal-title":"Blood"},{"key":"850_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0161-5890(00)00038-9","volume":"37","author":"D Dunn-Walters","year":"2000","unstructured":"Dunn-Walters, D., Boursier, L. & Spencer, J. Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions. Mol. Immunol. 37, 107\u2013113 (2000).","journal-title":"Mol. Immunol."},{"key":"850_CR27","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1073\/pnas.1711720115","volume":"115","author":"FS van de Bovenkamp","year":"2018","unstructured":"van de Bovenkamp, F. S. et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc. Natl Acad. Sci. USA 115, 1901\u20131906 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR28","doi-asserted-by":"crossref","unstructured":"Taylor, M. E. & Drickamer, K. Introduction to Glycobiology. (Oxford University Press, 2011).","DOI":"10.1093\/hesc\/9780199569113.001.0001"},{"key":"850_CR29","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.bbamcr.2013.04.001","volume":"1833","author":"M Aebi","year":"2013","unstructured":"Aebi, M. N-linked protein glycosylation in the ER. Biochim. Biophys. Acta Mol. Cell Res. 1833, 2430\u20132437 (2013).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"850_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tibs.2009.10.001","volume":"35","author":"M Aebi","year":"2010","unstructured":"Aebi, M., Bernasconi, R., Clerc, S. & Molinari, M. N-glycan structures: recognition and processing in the ER. Trends Biochem. Sci. 35, 74\u201382 (2010).","journal-title":"Trends Biochem. Sci."},{"key":"850_CR31","doi-asserted-by":"crossref","unstructured":"Breitling, J. & Aebi, M. N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol. 5, a013359 (2013).","DOI":"10.1101\/cshperspect.a013359"},{"key":"850_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1146\/annurev.bi.54.070185.003215","volume":"54","author":"R Kornfeld","year":"1985","unstructured":"Kornfeld, R. & Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631\u2013664 (1985).","journal-title":"Annu. Rev. Biochem."},{"key":"850_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00018-009-0126-z","volume":"67","author":"L Tu","year":"2010","unstructured":"Tu, L. & Banfield, D. K. Localization of Golgi-resident glycosyltransferases. Cell. Mol. Life Sci. 67, 29\u201341 (2010).","journal-title":"Cell. Mol. Life Sci."},{"key":"850_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.18388\/abp.1997_4411","volume":"44","author":"E Ja\u015bkiewicz","year":"1997","unstructured":"Ja\u015bkiewicz, E. Retention of glycosyltransferases in the Golgi apparatus. Acta Biochim. Pol. 44, 173\u2013179 (1997).","journal-title":"Acta Biochim. Pol."},{"key":"850_CR35","doi-asserted-by":"publisher","first-page":"38329","DOI":"10.1074\/jbc.M111.277681","volume":"286","author":"A Hassinen","year":"2011","unstructured":"Hassinen, A. et al. Functional organization of Golgi N- and O-glycosylation pathways involves pH-dependent complex formation that is impaired in cancer cells. J. Biol. Chem. 286, 38329\u201338340 (2011).","journal-title":"J. Biol. Chem."},{"key":"850_CR36","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1002\/pmic.200700289","volume":"7","author":"M Wuhrer","year":"2007","unstructured":"Wuhrer, M. et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 7, 4070\u20134081 (2007).","journal-title":"Proteomics"},{"key":"850_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0014-5793(00)01557-X","volume":"473","author":"K Masuda","year":"2000","unstructured":"Masuda, K. et al. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett. 473, 349\u2013357 (2000).","journal-title":"FEBS Lett."},{"key":"850_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1021\/pr800737u","volume":"8","author":"A Knezevi\u0107","year":"2009","unstructured":"Knezevi\u0107, A. et al. Variability, heritability and environmental determinants of human plasma N-glycome. J. Proteome Res. 8, 694\u2013701 (2009).","journal-title":"J. Proteome Res."},{"key":"850_CR39","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1074\/mcp.R112.026005","volume":"12","author":"G Zauner","year":"2013","unstructured":"Zauner, G. et al. Glycoproteomic analysis of antibodies. Mol. Cell Proteom. 12, 856\u2013865 (2013).","journal-title":"Mol. Cell Proteom."},{"key":"850_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbagen.2007.06.012","volume":"1780","author":"A Kobata","year":"2008","unstructured":"Kobata, A. The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles. Biochim. Biophys. Acta 1780, 472\u2013478 (2008).","journal-title":"Biochim. Biophys. Acta"},{"key":"850_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","volume":"333","author":"I Gudelj","year":"2018","unstructured":"Gudelj, I., Lauc, G. & Pezer, M. Immunoglobulin G glycosylation in aging and diseases. Cell. Immunol. 333, 65\u201379 (2018).","journal-title":"Cell. Immunol."},{"key":"850_CR42","doi-asserted-by":"publisher","first-page":"15222","DOI":"10.18632\/aging.103884","volume":"12","author":"J \u0160tambuk","year":"2020","unstructured":"\u0160tambuk, J. et al. Global variability of the human IgG glycome. Aging 12, 15222\u201315259 (2020).","journal-title":"Aging"},{"key":"850_CR43","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1074\/mcp.M113.037465","volume":"13","author":"JE Huffman","year":"2014","unstructured":"Huffman, J. E. et al. Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol. Cell Proteom. 13, 1598\u20131610 (2014).","journal-title":"Mol. Cell Proteom."},{"key":"850_CR44","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733\u201326740 (2002).","journal-title":"J. Biol. Chem."},{"key":"850_CR45","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1080\/19420862.2016.1218586","volume":"8","author":"GP Subedi","year":"2016","unstructured":"Subedi, G. P. & Barb, A. W. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc \u03b3 receptor. MAbs 8, 1512\u20131524 (2016).","journal-title":"MAbs"},{"key":"850_CR46","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay, J. et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122, 3482\u20133491 (2013).","journal-title":"Blood"},{"key":"850_CR47","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu.2017.00877","volume":"8","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front. Immunol. 8, 877 (2017).","journal-title":"Front. Immunol."},{"key":"850_CR48","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","volume":"108","author":"C Ferrara","year":"2011","unstructured":"Ferrara, C. et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc\u03b3RIII and antibodies lacking core fucose. Proc. Natl Acad. Sci. USA 108, 12669\u201312674 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR49","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1074\/jbc.M510171200","volume":"281","author":"C Ferrara","year":"2006","unstructured":"Ferrara, C., Stuart, F., Sondermann, P., Br\u00fcnker, P. & Uma\u00f1a, P. The carbohydrate at Fc\u03b3RIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281, 5032\u20135036 (2006).","journal-title":"J. Biol. Chem."},{"key":"850_CR50","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/glycob\/cwz101","volume":"30","author":"A Harbison","year":"2020","unstructured":"Harbison, A. & Fadda, E. An atomistic perspective on antibody-dependent cellular cytotoxicity quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics. Glycobiology 30, 407\u2013414 (2020).","journal-title":"Glycobiology"},{"key":"850_CR51","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4049\/jimmunol.1700116","volume":"199","author":"CW Bruggeman","year":"2017","unstructured":"Bruggeman, C. W. et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fc\u03b3 receptor profile. J. Immunol. 199, 204\u2013211 (2017).","journal-title":"J. Immunol."},{"key":"850_CR52","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-05-2619","volume":"12","author":"S Iida","year":"2006","unstructured":"Iida, S. et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to Fc\u03b3RIIIa. Clin. Cancer Res. 12, 2879\u20132887 (2006).","journal-title":"Clin. Cancer Res."},{"key":"850_CR53","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/glycob\/cwl057","volume":"17","author":"Y Kanda","year":"2007","unstructured":"Kanda, Y. et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17, 104\u2013118 (2007).","journal-title":"Glycobiology"},{"key":"850_CR54","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jmb.2004.01.007","volume":"336","author":"A Okazaki","year":"2004","unstructured":"Okazaki, A. et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and Fc\u03b3RIIIa. J. Mol. Biol. 336, 1239\u20131249 (2004).","journal-title":"J. Mol. Biol."},{"key":"850_CR55","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","volume":"124","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke, S. Q. et al. Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages. Blood 124, 3709\u20133718 (2014).","journal-title":"Blood"},{"key":"850_CR56","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","volume":"186","author":"L Bologna","year":"2011","unstructured":"Bologna, L. et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186, 3762\u20133769 (2011).","journal-title":"J. Immunol."},{"key":"850_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jim.2005.08.009","volume":"306","author":"R Niwa","year":"2005","unstructured":"Niwa, R. et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306, 151\u2013160 (2005).","journal-title":"J. Immunol. Methods"},{"key":"850_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/bjh.12965","volume":"166","author":"R Kapur","year":"2014","unstructured":"Kapur, R. et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br. J. Haematol. 166, 936\u2013945 (2014).","journal-title":"Br. J. Haematol."},{"key":"850_CR59","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clim.2005.10.008","volume":"118","author":"S Sib\u00e9ril","year":"2006","unstructured":"Sib\u00e9ril, S. et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc\u03b3R functions. Clin. Immunol. 118, 170\u2013179 (2006).","journal-title":"Clin. Immunol."},{"key":"850_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/bjh.14438","volume":"176","author":"ME Sonneveld","year":"2017","unstructured":"Sonneveld, M. E. et al. Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn. Br. J. Haematol. 176, 651\u2013660 (2017).","journal-title":"Br. J. Haematol."},{"key":"850_CR61","doi-asserted-by":"publisher","first-page":"339828","DOI":"10.1016\/j.aca.2022.339828","volume":"1209","author":"A Shrivastava","year":"2022","unstructured":"Shrivastava, A., Joshi, S., Guttman, A. & Rathore, A. S. N-glycosylation of monoclonal antibody therapeutics: a comprehensive review on significance and characterization. Anal. Chim. Acta 1209, 339828 (2022).","journal-title":"Anal. Chim. Acta"},{"key":"850_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrrheum.2018.8","volume":"14","author":"J McHugh","year":"2018","unstructured":"McHugh, J. Glycoengineering has therapeutic potential. Nat. Rev. Rheumatol. 14, 121\u2013121 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"850_CR63","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","volume":"10","author":"NA Pereira","year":"2018","unstructured":"Pereira, N. A., Chan, K. F., Lin, P. C. & Song, Z. The \u2018less-is-more\u2019 in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs 10, 693\u2013711 (2018).","journal-title":"MAbs"},{"key":"850_CR64","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101\u20131110 (2014).","journal-title":"N. Engl. J. Med."},{"key":"850_CR65","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrd2804","volume":"8","author":"R Jefferis","year":"2009","unstructured":"Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug. Discov. 8, 226\u2013234 (2009).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"850_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139828","volume":"10","author":"WJR Fokkink","year":"2015","unstructured":"Fokkink, W. J. R. et al. Comparison of Fc N-glycosylation of pharmaceutical products of intravenous immunoglobulin G. PLoS One 10, e0139828 (2015).","journal-title":"PLoS One"},{"key":"850_CR67","doi-asserted-by":"publisher","first-page":"M111.010090","DOI":"10.1074\/mcp.M111.010090","volume":"10","author":"M Puci\u0107","year":"2011","unstructured":"Puci\u0107, M. et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol. Cell Proteom. 10, M111.010090 (2011).","journal-title":"Mol. Cell Proteom."},{"key":"850_CR68","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1158\/0008-5472.CAN-04-4212","volume":"65","author":"M Schuster","year":"2005","unstructured":"Schuster, M. et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65, 7934\u20137941 (2005).","journal-title":"Cancer Res."},{"key":"850_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01525-0","volume":"8","author":"E Benedetti","year":"2017","unstructured":"Benedetti, E. et al. Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway. Nat. Commun. 8, 1483 (2017).","journal-title":"Nat. Commun."},{"key":"850_CR70","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/6179","volume":"17","author":"P Uma\u00f1a","year":"1999","unstructured":"Uma\u00f1a, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176\u2013180 (1999).","journal-title":"Nat. Biotechnol."},{"key":"850_CR71","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1021\/bp050228w","volume":"21","author":"J Hodoniczky","year":"2005","unstructured":"Hodoniczky, J., Zheng, Y. Z. & James, D. C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21, 1644\u20131652 (2005).","journal-title":"Biotechnol. Prog."},{"key":"850_CR72","doi-asserted-by":"publisher","first-page":"18975","DOI":"10.1021\/ja208390n","volume":"133","author":"G Zou","year":"2011","unstructured":"Zou, G. et al. Chemoenzymatic synthesis and Fc\u03b3 receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to Fc\u03b3IIIa receptor. J. Am. Chem. Soc. 133, 18975\u201318991 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"850_CR73","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/glycob\/5.8.813","volume":"5","author":"MR Lifely","year":"1995","unstructured":"Lifely, M. R., Hale, C., Boyce, S., Keen, M. J. & Phillips, J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5, 813\u2013822 (1995).","journal-title":"Glycobiology"},{"key":"850_CR74","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","volume":"167","author":"LL Lu","year":"2016","unstructured":"Lu, L. L. et al. A functional role for antibodies in tuberculosis. Cell 167, 433\u2013443.e14 (2016).","journal-title":"Cell"},{"key":"850_CR75","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0035-9203(96)90124-8","volume":"90","author":"C Pilkington","year":"1996","unstructured":"Pilkington, C., Basaran, M., Barlan, I., Costello, A. M. & Rook, G. A. Raised levels of agalactosyl IgG in childhood tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 90, 167\u2013168 (1996).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"850_CR76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/08916939508995306","volume":"22","author":"C Pilkington","year":"1995","unstructured":"Pilkington, C., Yeung, E., Isenberg, D., Lefvert, A. K. & Rook, G. A. Agalactosyl IgG and antibody specificity in rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis. Autoimmunity 22, 107\u2013111 (1995).","journal-title":"Autoimmunity"},{"key":"850_CR77","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0961203314558861","volume":"24","author":"C Sj\u00f6wall","year":"2015","unstructured":"Sj\u00f6wall, C. et al. Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. Lupus 24, 569\u2013581 (2015).","journal-title":"Lupus"},{"key":"850_CR78","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF00302151","volume":"12","author":"M Tomana","year":"1992","unstructured":"Tomana, M., Schrohenloher, R. E., Reveille, J. D., Arnett, F. C. & Koopman, W. J. Abnormal galactosylation of serum IgG in patients with systemic lupus erythematosus and members of families with high frequency of autoimmune diseases. Rheumatol. Int. 12, 191\u2013194 (1992).","journal-title":"Rheumatol. Int."},{"key":"850_CR79","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbadis.2018.03.018","volume":"1864","author":"I Gudelj","year":"2018","unstructured":"Gudelj, I. et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 2034\u20132039 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"850_CR80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.advms.2015.12.009","volume":"61","author":"E Gi\u0144dzie\u0144ska-Sie\u015bkiewicz","year":"2016","unstructured":"Gi\u0144dzie\u0144ska-Sie\u015bkiewicz, E. et al. Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate. Adv. Med. Sci. 61, 193\u2013197 (2016).","journal-title":"Adv. Med. Sci."},{"key":"850_CR81","doi-asserted-by":"publisher","first-page":"R193","DOI":"10.1186\/ar2892","volume":"11","author":"FE van de Geijn","year":"2009","unstructured":"van de Geijn, F. E. et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther. 11, R193 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"850_CR82","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/art.27533","volume":"62","author":"A Ercan","year":"2010","unstructured":"Ercan, A. et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 62, 2239\u20132248 (2010).","journal-title":"Arthritis Rheum."},{"key":"850_CR83","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2013-203565","volume":"74","author":"Y Rombouts","year":"2015","unstructured":"Rombouts, Y. et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann. Rheum. Dis. 74, 234\u2013241 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"850_CR84","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/gut.31.4.431","volume":"31","author":"R Dub\u00e9","year":"1990","unstructured":"Dub\u00e9, R. et al. Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut 31, 431\u2013434 (1990).","journal-title":"Gut"},{"key":"850_CR85","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2018.01.002","volume":"154","author":"M \u0160imurina","year":"2018","unstructured":"\u0160imurina, M. et al. Glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases. Gastroenterology 154, 1320\u20131333.e10 (2018).","journal-title":"Gastroenterology"},{"key":"850_CR86","first-page":"1237","volume":"21","author":"I Trbojevi\u0107 Akma\u010di\u0107","year":"2015","unstructured":"Trbojevi\u0107 Akma\u010di\u0107, I. et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm. Bowel Dis. 21, 1237\u20131247 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"850_CR87","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ibd.21459","volume":"17","author":"S Nakajima","year":"2011","unstructured":"Nakajima, S. et al. Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm. Bowel Dis. 17, 927\u2013936 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"850_CR88","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/jaut.1996.0104","volume":"10","author":"A Bond","year":"1997","unstructured":"Bond, A. et al. A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. J. Autoimmun. 10, 77\u201385 (1997).","journal-title":"J. Autoimmun."},{"key":"850_CR89","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1365-2249.1996.d01-741.x","volume":"105","author":"A Bond","year":"1996","unstructured":"Bond, A., Alavi, A., Axford, J. S., Youinou, P. & Hay, F. C. The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sj\u00f6gren\u2019s syndrome (SS). Clin. Exp. Immunol. 105, 99\u2013103 (1996).","journal-title":"Clin. Exp. Immunol."},{"key":"850_CR90","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ebiom.2017.01.033","volume":"17","author":"MJ Kemna","year":"2017","unstructured":"Kemna, M. J. et al. Galactosylation and sialylation levels of IgG predict relapse in patients with PR3-ANCA associated vasculitis. EBioMedicine 17, 108\u2013118 (2017).","journal-title":"EBioMedicine"},{"key":"850_CR91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1365-2249.2002.01864.x","volume":"129","author":"M Holland","year":"2002","unstructured":"Holland, M. et al. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin. Exp. Immunol. 129, 183\u2013190 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"850_CR92","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.bbagen.2005.11.021","volume":"1760","author":"M Holland","year":"2006","unstructured":"Holland, M. et al. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim. Biophys. Acta 1760, 669\u2013677 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"850_CR93","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/pr1004373","volume":"10","author":"MHJ Selman","year":"2011","unstructured":"Selman, M. H. J. et al. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J. Proteome Res. 10, 143\u2013152 (2011).","journal-title":"J. Proteome Res."},{"key":"850_CR94","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/pr401213z","volume":"13","author":"W-JR Fokkink","year":"2014","unstructured":"Fokkink, W.-J. R. et al. IgG Fc N-glycosylation in Guillain-Barr\u00e9 syndrome treated with immunoglobulins. J. Proteome Res. 13, 1722\u20131730 (2014).","journal-title":"J. Proteome Res."},{"key":"850_CR95","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/01.aids.0000161767.21405.68","volume":"19","author":"JS Moore","year":"2005","unstructured":"Moore, J. S. et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 19, 381\u2013389 (2005).","journal-title":"AIDS"},{"key":"850_CR96","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1172\/JCI65708","volume":"123","author":"ME Ackerman","year":"2013","unstructured":"Ackerman, M. E. et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123, 2183\u20132192 (2013).","journal-title":"J. Clin. Invest."},{"key":"850_CR97","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nm.4105","volume":"22","author":"M Vaccari","year":"2016","unstructured":"Vaccari, M. et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat. Med. 22, 762\u2013770 (2016).","journal-title":"Nat. Med."},{"key":"850_CR98","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/infdis\/jiu388","volume":"211","author":"C-H Ho","year":"2015","unstructured":"Ho, C.-H. et al. Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy. J. Infect. Dis. 211, 115\u2013124 (2015).","journal-title":"J. Infect. Dis."},{"key":"850_CR99","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1128\/JVI.01600-07","volume":"82","author":"AS Mehta","year":"2008","unstructured":"Mehta, A. S. et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J. Virol. 82, 1259\u20131270 (2008).","journal-title":"J. Virol."},{"key":"850_CR100","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/0161-5890(95)00118-2","volume":"32","author":"PN Boyd","year":"1995","unstructured":"Boyd, P. N., Lines, A. C. & Patel, A. K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32, 1311\u20131318 (1995).","journal-title":"Mol. Immunol."},{"key":"850_CR101","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2017.00646","volume":"8","author":"B Peschke","year":"2017","unstructured":"Peschke, B., Keller, C. W., Weber, P., Quast, I. & L\u00fcnemann, J. D. Fc-Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front. Immunol. 8, 646 (2017).","journal-title":"Front. Immunol."},{"key":"850_CR102","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nm0395-237","volume":"1","author":"R Malhotra","year":"1995","unstructured":"Malhotra, R. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1, 237\u2013243 (1995).","journal-title":"Nat. Med."},{"key":"850_CR103","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2018.00553","volume":"9","author":"G Dekkers","year":"2018","unstructured":"Dekkers, G., Rispens, T. & Vidarsson, G. Novel concepts of altered immunoglobulin G galactosylation in autoimmune diseases. Front. Immunol. 9, 553 (2018).","journal-title":"Front. Immunol."},{"key":"850_CR104","first-page":"285","volume":"16","author":"N Tsuchiya","year":"1989","unstructured":"Tsuchiya, N. et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J. Rheumatol. 16, 285\u2013290 (1989).","journal-title":"J. Rheumatol."},{"key":"850_CR105","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.bbagen.2005.10.002","volume":"1760","author":"Y Yamaguchi","year":"2006","unstructured":"Yamaguchi, Y. et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim. Biophys. Acta Gen. Subj. 1760, 693\u2013700 (2006).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"850_CR106","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/intimm\/dxx038","volume":"29","author":"M Kiyoshi","year":"2017","unstructured":"Kiyoshi, M., Tsumoto, K., Ishii-Watabe, A. & Caaveiro, J. M. M. Glycosylation of IgG-Fc: a molecular perspective. Int. Immunol. 29, 311\u2013317 (2017).","journal-title":"Int. Immunol."},{"key":"850_CR107","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.1073\/pnas.0702936104","volume":"104","author":"F Nimmerjahn","year":"2007","unstructured":"Nimmerjahn, F., Anthony, R. M. & Ravetch, J. V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl Acad. Sci. USA 104, 8433\u20138437 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR108","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/rheumatology\/ken226","volume":"47","author":"FE van de Geijn","year":"2008","unstructured":"van de Geijn, F. E. et al. Mannose-binding lectin polymorphisms are not associated with rheumatoid arthritis \u2014 confirmation in two large cohorts. Rheumatology 47, 1168\u20131171 (2008).","journal-title":"Rheumatology"},{"key":"850_CR109","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/ar3231","volume":"13","author":"FE van de Geijn","year":"2011","unstructured":"van de Geijn, F. E. et al. Mannose-binding lectin does not explain the course and outcome of pregnancy in rheumatoid arthritis. Arthritis Res. Ther. 13, R10 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"850_CR110","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","volume":"18","author":"CM Karsten","year":"2012","unstructured":"Karsten, C. M. et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc\u03b3RIIB and dectin-1. Nat. Med. 18, 1401\u20131406 (2012).","journal-title":"Nat. Med."},{"key":"850_CR111","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbrc.2016.09.038","volume":"479","author":"KA Heyl","year":"2016","unstructured":"Heyl, K. A., Karsten, C. M. & Slevogt, H. Galectin-3 binds highly galactosylated IgG1 and is crucial for the IgG1 complex mediated inhibition of C5aReceptor induced immune responses. Biochem. Biophys. Res. Commun. 479, 86\u201390 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"850_CR112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2013.09.001","volume":"47","author":"K Yamada","year":"2013","unstructured":"Yamada, K. et al. Galactosylation of IgG1 modulates Fc\u03b3RIIB-mediated inhibition of murine autoimmune hemolytic anemia. J. Autoimmun. 47, 104\u2013110 (2013).","journal-title":"J. Autoimmun."},{"key":"850_CR113","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1074\/mcp.M900540-MCP200","volume":"9","author":"D Houde","year":"2010","unstructured":"Houde, D., Peng, Y., Berkowitz, S. A. & Engen, J. R. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell Proteom. 9, 1716\u20131728 (2010).","journal-title":"Mol. Cell Proteom."},{"key":"850_CR114","first-page":"143","volume":"5","author":"BM Kumpel","year":"1994","unstructured":"Kumpel, B. M., Rademacher, T. W., Rook, G. A., Williams, P. J. & Wilson, I. B. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibodies Hybrid. 5, 143\u2013151 (1994).","journal-title":"Hum. Antibodies Hybrid."},{"key":"850_CR115","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3233\/HAB-1995-6301","volume":"6","author":"BM Kumpel","year":"1995","unstructured":"Kumpel, B. M., Wang, Y., Griffiths, H. L., Hadley, A. G. & Rook, G. A. The biological activity of human monoclonal IgG anti-D is reduced by \u03b2-galactosidase treatment. Hum. Antibodies Hybrid. 6, 82\u201388 (1995).","journal-title":"Hum. Antibodies Hybrid."},{"key":"850_CR116","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2016.03.002","volume":"73","author":"M Thomann","year":"2016","unstructured":"Thomann, M., Reckermann, K., Reusch, D., Prasser, J. & Tejada, M. L. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol. Immunol. 73, 69\u201375 (2016).","journal-title":"Mol. Immunol."},{"key":"850_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134949","volume":"10","author":"M Thomann","year":"2015","unstructured":"Thomann, M. et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One 10, e0134949 (2015).","journal-title":"PLoS One"},{"key":"850_CR118","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670\u2013673 (2006).","journal-title":"Science"},{"key":"850_CR119","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1073\/pnas.1702173114","volume":"114","author":"T Li","year":"2017","unstructured":"Li, T. et al. Modulating IgG effector function by Fc glycan engineering. Proc. Natl Acad. Sci. USA 114, 3485\u20133490 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR120","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.molimm.2006.09.005","volume":"44","author":"BJ Scallon","year":"2007","unstructured":"Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N. & Raju, T. S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44, 1524\u20131534 (2007).","journal-title":"Mol. Immunol."},{"key":"850_CR121","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/art.42098","volume":"74","author":"T Kissel","year":"2022","unstructured":"Kissel, T. et al. IgG anti-citrullinated protein antibody variable domain glycosylation increases before the onset of rheumatoid arthritis and stabilizes thereafter: a cross-sectional study encompassing ~1,500 samples. Arthritis Rheumatol. 74, 1147\u20131158 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"850_CR122","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1172\/JCI115643","volume":"89","author":"JS Axford","year":"1992","unstructured":"Axford, J. S. et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J. Clin. Invest. 89, 1021\u20131031 (1992).","journal-title":"J. Clin. Invest."},{"key":"850_CR123","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1021\/pr400589m","volume":"12","author":"A Bondt","year":"2013","unstructured":"Bondt, A. et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J. Proteome Res. 12, 4522\u20134531 (2013).","journal-title":"J. Proteome Res."},{"key":"850_CR124","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2009090984","volume":"21","author":"MM van Timmeren","year":"2010","unstructured":"van Timmeren, M. M. et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J. Am. Soc. Nephrol. 21, 1103\u20131114 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR125","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1021\/pr500780a","volume":"14","author":"M Wuhrer","year":"2015","unstructured":"Wuhrer, M. et al. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation. J. Proteome Res. 14, 1657\u20131665 (2015).","journal-title":"J. Proteome Res."},{"key":"850_CR126","first-page":"1243","volume":"61","author":"L Tingting","year":"2021","unstructured":"Tingting, L. et al. Characteristics of purified Anti-\u03b22GPI IgG N-glycosylation associate with thrombotic, obstetric, and catastrophic antiphospholipid syndrome. Rheumatology 61, 1243\u20131254 (2021).","journal-title":"Rheumatology"},{"key":"850_CR127","first-page":"247","volume":"31","author":"I Aurer","year":"2007","unstructured":"Aurer, I. et al. Aberrant glycosylation of Igg heavy chain in multiple myeloma. Coll. Antropol. 31, 247\u2013251 (2007).","journal-title":"Coll. Antropol."},{"key":"850_CR128","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3389\/fimmu.2020.00854","volume":"11","author":"A Bosseboeuf","year":"2020","unstructured":"Bosseboeuf, A. et al. Analysis of the targets and glycosylation of monoclonal IgAs From MGUS and myeloma patients. Front. Immunol. 11, 854 (2020).","journal-title":"Front. Immunol."},{"key":"850_CR129","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1021\/acs.jproteome.6b00768","volume":"16","author":"S Mittermayr","year":"2017","unstructured":"Mittermayr, S. et al. Polyclonal immunoglobulin G N-glycosylation in the pathogenesis of plasma cell disorders. J. Proteome Res. 16, 748\u2013762 (2017).","journal-title":"J. Proteome Res."},{"key":"850_CR130","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/j.jprot.2012.02.001","volume":"75","author":"G Chen","year":"2012","unstructured":"Chen, G. et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J. Proteom. 75, 2824\u20132834 (2012).","journal-title":"J. Proteom."},{"key":"850_CR131","first-page":"715","volume":"28","author":"Y Kanoh","year":"2008","unstructured":"Kanoh, Y., Ohara, T., Tadano, T., Kanoh, M. & Akahoshi, T. Changes to N-linked oligosaccharide chains of human serum immunoglobulin G and matrix metalloproteinase-2 with cancer progression. Anticancer. Res. 28, 715\u2013720 (2008).","journal-title":"Anticancer. Res."},{"key":"850_CR132","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000079484","volume":"66","author":"Y Kanoh","year":"2004","unstructured":"Kanoh, Y. et al. Analysis of the oligosaccharide chain of human serum immunoglobulin G in patients with localized or metastatic cancer. Oncology 66, 365\u2013370 (2004).","journal-title":"Oncology"},{"key":"850_CR133","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373\u2013376 (2008).","journal-title":"Science"},{"key":"850_CR134","doi-asserted-by":"publisher","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","volume":"112","author":"N Washburn","year":"2015","unstructured":"Washburn, N. et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc. Natl Acad. Sci. USA 112, E1297\u2013E1306 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR135","doi-asserted-by":"publisher","first-page":"19571","DOI":"10.1073\/pnas.0810163105","volume":"105","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M., Wermeling, F., Karlsson, M. C. I. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 105, 19571\u201319578 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR136","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","volume":"18","author":"P Bruhns","year":"2003","unstructured":"Bruhns, P., Samuelsson, A., Pollard, J. W. & Ravetch, J. V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18, 573\u2013581 (2003).","journal-title":"Immunity"},{"key":"850_CR137","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature10134","volume":"475","author":"RM Anthony","year":"2011","unstructured":"Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475, 110\u2013113 (2011).","journal-title":"Nature"},{"key":"850_CR138","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nm1416","volume":"12","author":"V Siragam","year":"2006","unstructured":"Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc\u03b3 receptors on dendritic cells. Nat. Med. 12, 688\u2013692 (2006).","journal-title":"Nat. Med."},{"key":"850_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021246","volume":"6","author":"T Guhr","year":"2011","unstructured":"Guhr, T. et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 6, e21246 (2011).","journal-title":"PLoS One"},{"key":"850_CR140","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.4049\/jimmunol.1301611","volume":"192","author":"IK Campbell","year":"2014","unstructured":"Campbell, I. K. et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J. Immunol. 192, 5031\u20135038 (2014).","journal-title":"J. Immunol."},{"key":"850_CR141","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/j.1537-2995.2011.03517.x","volume":"52","author":"D Leontyev","year":"2012","unstructured":"Leontyev, D. et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52, 1799\u20131805 (2012).","journal-title":"Transfusion"},{"key":"850_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037243","volume":"7","author":"F K\u00e4sermann","year":"2012","unstructured":"K\u00e4sermann, F. et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 7, e37243 (2012).","journal-title":"PLoS One"},{"key":"850_CR143","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nri3401-c1","volume":"14","author":"S von Gunten","year":"2014","unstructured":"von Gunten, S. et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat. Rev. Immunol. 14, 349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"850_CR144","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.4049\/jimmunol.1301260","volume":"192","author":"ASW Tjon","year":"2014","unstructured":"Tjon, A. S. W. et al. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production. J. Immunol. 192, 5625\u20135634 (2014).","journal-title":"J. Immunol."},{"key":"850_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/srep05672","volume":"4","author":"M Sharma","year":"2014","unstructured":"Sharma, M. et al. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Sci. Rep. 4, 5672 (2014).","journal-title":"Sci. Rep."},{"key":"850_CR146","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2011.01.002","volume":"139","author":"M Siedlar","year":"2011","unstructured":"Siedlar, M. et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+ CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin. Immunol. 139, 122\u2013132 (2011).","journal-title":"Clin. Immunol."},{"key":"850_CR147","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/rheumatology\/keh488","volume":"44","author":"T Ichiyama","year":"2005","unstructured":"Ichiyama, T. et al. Intravenous immunoglobulin does not increase Fc\u03b3RIIB expression on monocytes\/macrophages during acute Kawasaki disease. Rheumatology 44, 314\u2013317 (2005).","journal-title":"Rheumatology"},{"key":"850_CR148","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2249.2012.04591.x","volume":"169","author":"M Shimomura","year":"2012","unstructured":"Shimomura, M. et al. Intravenous immunoglobulin does not increase Fc\u03b3RIIB expression levels on monocytes in children with immune thrombocytopenia. Clin. Exp. Immunol. 169, 33\u201337 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"850_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46484-2","volume":"9","author":"AR Temming","year":"2019","unstructured":"Temming, A. R. et al. Human DC-SIGN and CD23 do not interact with human IgG. Sci. Rep. 9, 10 (2019).","journal-title":"Sci. Rep."},{"key":"850_CR150","doi-asserted-by":"publisher","first-page":"9723","DOI":"10.1021\/ja4014375","volume":"135","author":"X Yu","year":"2013","unstructured":"Yu, X. et al. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J. Am. Chem. Soc. 135, 9723\u20139732 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"850_CR151","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.coi.2008.06.007","volume":"20","author":"TS Raju","year":"2008","unstructured":"Raju, T. S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20, 471\u2013478 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"850_CR152","doi-asserted-by":"publisher","first-page":"E3544","DOI":"10.1073\/pnas.1310657110","volume":"110","author":"M Crispin","year":"2013","unstructured":"Crispin, M., Yu, X. & Bowden, T. A. Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc. Natl Acad. Sci. USA 110, E3544\u20133546 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR153","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/acs.biochem.5b01323","volume":"55","author":"J Fang","year":"2016","unstructured":"Fang, J., Richardson, J., Du, Z. & Zhang, Z. Effect of Fc-glycan structure on the conformational stability of IgG revealed by hydrogen\/deuterium exchange and limited proteolysis. Biochemistry 55, 860\u2013868 (2016).","journal-title":"Biochemistry"},{"key":"850_CR154","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1021\/bi300319q","volume":"51","author":"AW Barb","year":"2012","unstructured":"Barb, A. W. et al. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 51, 4618\u20134626 (2012).","journal-title":"Biochemistry"},{"key":"850_CR155","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/19420862.2019.1655377","volume":"11","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z., Shah, B. & Richardson, J. Impact of Fc N-glycan sialylation on IgG structure. MAbs 11, 1381\u20131390 (2019).","journal-title":"MAbs"},{"key":"850_CR156","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1016\/S0021-9258(18)53140-9","volume":"268","author":"LD Powell","year":"1993","unstructured":"Powell, L. D., Sgroi, D., Sjoberg, E. R., Stamenkovic, I. & Varki, A. Natural ligands of the B cell adhesion molecule CD22\u03b2 carry N-linked oligosaccharides with \u0251-2,6-linked sialic acids that are required for recognition. J. Biol. Chem. 268, 7019\u20137027 (1993).","journal-title":"J. Biol. Chem."},{"key":"850_CR157","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jaci.2013.09.029","volume":"133","author":"AH Massoud","year":"2014","unstructured":"Massoud, A. H. et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J. Allergy Clin. Immunol. 133, 853\u2013863.e5 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"850_CR158","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2009-12-261461","volume":"116","author":"J-F S\u00e9\u00eft\u00e9","year":"2010","unstructured":"S\u00e9\u00eft\u00e9, J.-F. et al. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116, 1698\u20131704 (2010).","journal-title":"Blood"},{"key":"850_CR159","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.06.026","volume":"162","author":"TT Wang","year":"2015","unstructured":"Wang, T. T. et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162, 160\u2013169 (2015).","journal-title":"Cell"},{"key":"850_CR160","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1172\/JCI82695","volume":"125","author":"I Quast","year":"2015","unstructured":"Quast, I. et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J. Clin. Invest. 125, 4160\u20134170 (2015).","journal-title":"J. Clin. Invest."},{"key":"850_CR161","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1084\/jem.168.3.1099","volume":"168","author":"SC Wallick","year":"1988","unstructured":"Wallick, S. C., Kabat, E. A. & Morrison, S. L. Glycosylation of a VH residue of a monoclonal antibody against alpha (1\u20136) dextran increases its affinity for antigen. J. Exp. Med. 168, 1099\u20131109 (1988).","journal-title":"J. Exp. Med."},{"key":"850_CR162","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/A:1007980032042","volume":"23","author":"H Tachibana","year":"1997","unstructured":"Tachibana, H., Kim, J. Y. & Shirahata, S. Building high affinity human antibodies by altering the glycosylation on the light chain variable region in N-acetylglucosamine-supplemented hybridoma cultures. Cytotechnology 23, 151\u2013159 (1997).","journal-title":"Cytotechnology"},{"key":"850_CR163","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1042\/bj3380529","volume":"338","author":"H Leibiger","year":"1999","unstructured":"Leibiger, H., W\u00fcstner, D., Stigler, R. D. & Marx, U. Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. Biochem. J. 338, 529\u2013538 (1999).","journal-title":"Biochem. J."},{"key":"850_CR164","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/j.1460-2075.1991.tb07819.x","volume":"10","author":"A Wright","year":"1991","unstructured":"Wright, A., Tao, M. H., Kabat, E. A. & Morrison, S. L. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J. 10, 2717\u20132723 (1991).","journal-title":"EMBO J."},{"key":"850_CR165","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13075-016-1172-1","volume":"18","author":"A Bondt","year":"2016","unstructured":"Bondt, A., Wuhrer, M., Kuijper, T. M., Hazes, J. M. W. & Dolhain, R. J. E. M. Fab glycosylation of immunoglobulin G does not associate with improvement of rheumatoid arthritis during pregnancy. Arthritis Res. Ther. 18, 274 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"850_CR166","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/art.40920","volume":"71","author":"L Hafkenscheid","year":"2019","unstructured":"Hafkenscheid, L. et al. N-linked glycans in the variable domain of IgG anti-citrullinated protein antibodies predict the development of rheumatoid arthritis. Arthritis Rheumatol. 71, 1626\u20131633 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"850_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213215","volume":"14","author":"OM Lardinois","year":"2019","unstructured":"Lardinois, O. M. et al. Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. PLoS One 14, e0213215 (2019).","journal-title":"PLoS One"},{"key":"850_CR168","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4049\/jimmunol.1502136","volume":"196","author":"FS van de Bovenkamp","year":"2016","unstructured":"van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. & Rombouts, Y. The emerging importance of IgG fab glycosylation in immunity. J. Immunol. 196, 1435\u20131441 (2016).","journal-title":"J. Immunol."},{"key":"850_CR169","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2172-13-10","volume":"13","author":"P-C Xu","year":"2012","unstructured":"Xu, P.-C. et al. Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies. BMC Immunol. 13, 10 (2012).","journal-title":"BMC Immunol."},{"key":"850_CR170","doi-asserted-by":"publisher","first-page":"18587","DOI":"10.1073\/pnas.1009388107","volume":"107","author":"V Coelho","year":"2010","unstructured":"Coelho, V. et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc. Natl Acad. Sci. USA 107, 18587\u201318592 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR171","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1182\/blood-2014-11-609404","volume":"125","author":"D Schneider","year":"2015","unstructured":"Schneider, D. et al. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood 125, 3287\u20133296 (2015).","journal-title":"Blood"},{"key":"850_CR172","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.4049\/jimmunol.2100820","volume":"208","author":"KL Wong","year":"2022","unstructured":"Wong, K. L. et al. SM03, an znti-CD22 antibody, converts cis-to-trans ligand binding of CD22 against \u03b12,6-linked sialic acid glycans and immunomodulates systemic autoimmune diseases. J. Immunol. 208, 2726\u20132737 (2022).","journal-title":"J. Immunol."},{"key":"850_CR173","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.2021012052","volume":"138","author":"G Chiodin","year":"2021","unstructured":"Chiodin, G. et al. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood 138, 1570\u20131582 (2021).","journal-title":"Blood"},{"key":"850_CR174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082558","volume":"8","author":"C Menni","year":"2013","unstructured":"Menni, C. et al. Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. PLoS One 8, e82558 (2013).","journal-title":"PLoS One"},{"key":"850_CR175","doi-asserted-by":"publisher","first-page":"9608","DOI":"10.1074\/jbc.273.16.9608","volume":"273","author":"AK Datta","year":"1998","unstructured":"Datta, A. K., Sinha, A. & Paulson, J. C. Mutation of the sialyltransferase S-sialylmotif alters the kinetics of the donor and acceptor substrates. J. Biol. Chem. 273, 9608\u20139614 (1998).","journal-title":"J. Biol. Chem."},{"key":"850_CR176","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003225","volume":"9","author":"G Lauc","year":"2013","unstructured":"Lauc, G. et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 9, e1003225 (2013).","journal-title":"PLoS Genet."},{"key":"850_CR177","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/hmg\/ddab072","volume":"30","author":"AS Shadrina","year":"2021","unstructured":"Shadrina, A. S. et al. Multivariate genome-wide analysis of immunoglobulin G N-glycosylation identifies new loci pleiotropic with immune function. Hum. Mol. Genet. 30, 1259\u20131270 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"850_CR178","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fimmu.2018.00277","volume":"9","author":"A Wahl","year":"2018","unstructured":"Wahl, A. et al. Genome-wide association study on immunoglobulin G glycosylation patterns. Front. Immunol. 9, 277 (2018).","journal-title":"Front. Immunol."},{"key":"850_CR179","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1615\/CritRevEukarGeneExpr.v16.i1.30","volume":"16","author":"HJ Whiteman","year":"2006","unstructured":"Whiteman, H. J. & Farrell, P. J. RUNX expression and function in human B cells. Crit. Rev. Eukaryot. Gene Expr. 16, 31\u201344 (2006).","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"850_CR180","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2013-01-480244","volume":"122","author":"B Niebuhr","year":"2013","unstructured":"Niebuhr, B. et al. Runx1 is essential at two stages of early murine B-cell development. Blood 122, 413\u2013423 (2013).","journal-title":"Blood"},{"key":"850_CR181","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1084\/jem.20082311","volume":"206","author":"M Sellars","year":"2009","unstructured":"Sellars, M., Reina-San-Martin, B., Kastner, P. & Chan, S. Ikaros controls isotype selection during immunoglobulin class switch recombination. J. Exp. Med. 206, 1073\u20131087 (2009).","journal-title":"J. Exp. Med."},{"key":"850_CR182","first-page":"1130","volume":"77","author":"A Bondt","year":"2018","unstructured":"Bondt, A. et al. ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis. Ann. Rheum. Dis. 77, 1130\u20131136 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"850_CR183","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/ard.47.2.91","volume":"47","author":"JM Pekelharing","year":"1988","unstructured":"Pekelharing, J. M., Hepp, E., Kamerling, J. P., Gerwig, G. J. & Leijnse, B. Alterations in carbohydrate composition of serum IgG from patients with rheumatoid arthritis and from pregnant women. Ann. Rheum. Dis. 47, 91\u201395 (1988).","journal-title":"Ann. Rheum. Dis."},{"key":"850_CR184","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0896-8411(91)90173-A","volume":"4","author":"GA Rook","year":"1991","unstructured":"Rook, G. A. et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J. Autoimmun. 4, 779\u2013794 (1991).","journal-title":"J. Autoimmun."},{"key":"850_CR185","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/gerona\/glt190","volume":"69","author":"J Kri\u0161ti\u0107","year":"2014","unstructured":"Kri\u0161ti\u0107, J. et al. Glycans are a novel biomarker of chronological and biological ages. J. Gerontol. A Biol. Sci. Med. Sci. 69, 779\u2013789 (2014).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"850_CR186","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89703","volume":"2","author":"A Ercan","year":"2017","unstructured":"Ercan, A. et al. Estrogens regulate glycosylation of IgG in women and men. JCI Insight 2, e89703 (2017).","journal-title":"JCI Insight"},{"key":"850_CR187","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-018-1586-z","volume":"20","author":"C Engdahl","year":"2018","unstructured":"Engdahl, C. et al. Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women. Arthritis Res. Ther. 20, 84 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"850_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106387","volume":"83","author":"N Du","year":"2020","unstructured":"Du, N. et al. Phytoestrogens protect joints in collagen induced arthritis by increasing IgG glycosylation and reducing osteoclast activation. Int. Immunopharmacol. 83, 106387 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"850_CR189","first-page":"303","volume":"112","author":"F Dall\u2019Olio","year":"2021","unstructured":"Dall\u2019Olio, F., Malagolini, N. & Immunoglobulin, G. Glycosylation changes in aging and other inflammatory conditions. Exp. Suppl. 112, 303\u2013340 (2021).","journal-title":"Exp. Suppl."},{"key":"850_CR190","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.arr.2012.02.002","volume":"12","author":"F Dall\u2019Olio","year":"2013","unstructured":"Dall\u2019Olio, F. et al. N-glycomic biomarkers of biological aging and longevity: a link with inflammaging. Ageing Res. Rev. 12, 685\u2013698 (2013).","journal-title":"Ageing Res. Rev."},{"key":"850_CR191","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1084\/jem.167.5.1731","volume":"167","author":"R Parekh","year":"1988","unstructured":"Parekh, R., Roitt, I., Isenberg, D., Dwek, R. & Rademacher, T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J. Exp. Med. 167, 1731\u20131736 (1988).","journal-title":"J. Exp. Med."},{"key":"850_CR192","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/glycob\/cwq051","volume":"20","author":"A Knezevic","year":"2010","unstructured":"Knezevic, A. et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 20, 959\u2013969 (2010).","journal-title":"Glycobiology"},{"key":"850_CR193","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1021\/acs.jproteome.6b00038","volume":"15","author":"N de Haan","year":"2016","unstructured":"de Haan, N., Reiding, K. R., Driessen, G., van der Burg, M. & Wuhrer, M. Changes in healthy human IgG Fc-glycosylation after birth and during early childhood. J. Proteome Res. 15, 1853\u20131861 (2016).","journal-title":"J. Proteome Res."},{"key":"850_CR194","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/glycob\/cws062","volume":"22","author":"M Pucic","year":"2012","unstructured":"Pucic, M. et al. Changes in plasma and IgG N-glycome during childhood and adolescence. Glycobiology 22, 975\u2013982 (2012).","journal-title":"Glycobiology"},{"key":"850_CR195","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1023\/A:1018582930906","volume":"14","author":"E Yamada","year":"1997","unstructured":"Yamada, E., Tsukamoto, Y., Sasaki, R., Yagyu, K. & Takahashi, N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj. J. 14, 401\u2013405 (1997).","journal-title":"Glycoconj. J."},{"key":"850_CR196","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/rej.2007.0556","volume":"10","author":"V Vanhooren","year":"2007","unstructured":"Vanhooren, V. et al. N-glycomic changes in serum proteins during human aging. Rejuvenation Res. 10, 521\u2013531a (2007).","journal-title":"Rejuvenation Res."},{"key":"850_CR197","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004112","volume":"95","author":"X Yu","year":"2016","unstructured":"Yu, X. et al. Profiling IgG N-glycans as potential biomarker of chronological and biological ages: a community-based study in a Han Chinese population. Medicine 95, e4112 (2016).","journal-title":"Medicine"},{"key":"850_CR198","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1084\/jem.20100064","volume":"207","author":"M Batten","year":"2010","unstructured":"Batten, M. et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 207, 2895\u20132906 (2010).","journal-title":"J. Exp. Med."},{"key":"850_CR199","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3389\/fimmu.2018.01183","volume":"9","author":"YC Bartsch","year":"2018","unstructured":"Bartsch, Y. C. et al. Sialylated autoantigen-reactive IgG antibodies attenuate disease development in autoimmune mouse models of lupus nephritis and rheumatoid arthritis. Front. Immunol. 9, 1183 (2018).","journal-title":"Front. Immunol."},{"key":"850_CR200","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1172\/JCI65938","volume":"123","author":"C Hess","year":"2013","unstructured":"Hess, C. et al. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 123, 3788\u20133796 (2013).","journal-title":"J. Clin. Invest."},{"key":"850_CR201","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jaci.2020.04.059","volume":"146","author":"YC Bartsch","year":"2020","unstructured":"Bartsch, Y. C. et al. IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants. J. Allergy Clin. Immunol. 146, 652\u2013666.e11 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"850_CR202","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3579","volume":"18","author":"R Pfeifle","year":"2017","unstructured":"Pfeifle, R. et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat. Immunol. 18, 104\u2013113 (2017).","journal-title":"Nat. Immunol."},{"key":"850_CR203","doi-asserted-by":"publisher","first-page":"107001","DOI":"10.1289\/EHP1612","volume":"125","author":"A Cardenas","year":"2017","unstructured":"Cardenas, A. et al. Plasma concentrations of per- and polyfluoroalkyl substances at baseline and associations with glycemic indicators and diabetes incidence among high-risk adults in the diabetes prevention program trial. Env. Health Perspect. 125, 107001 (2017).","journal-title":"Env. Health Perspect."},{"key":"850_CR204","doi-asserted-by":"publisher","first-page":"067012","DOI":"10.1289\/EHP1203","volume":"125","author":"W Zhou","year":"2017","unstructured":"Zhou, W. et al. Plasma perfluoroalkyl and polyfluoroalkyl substances concentration and menstrual cycle characteristics in preconception women. Env. Health Perspect. 125, 067012 (2017).","journal-title":"Env. Health Perspect."},{"key":"850_CR205","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.envint.2013.03.008","volume":"57\u201358","author":"T Fletcher","year":"2013","unstructured":"Fletcher, T. et al. Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. Env. Int. 57\u201358, 2\u201310 (2013).","journal-title":"Env. Int."},{"key":"850_CR206","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.chemosphere.2017.06.023","volume":"184","author":"R Siebenaler","year":"2017","unstructured":"Siebenaler, R. et al. Serum perfluoroalkyl acids (PFAAs) and associations with behavioral attributes. Chemosphere 184, 687\u2013693 (2017).","journal-title":"Chemosphere"},{"key":"850_CR207","doi-asserted-by":"publisher","first-page":"114285","DOI":"10.1016\/j.envpol.2020.114285","volume":"265","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Associations between the serum levels of PFOS\/PFOA and IgG N-glycosylation in adult or children. Environ. Pollut. 265, 114285 (2020).","journal-title":"Environ. Pollut."},{"key":"850_CR208","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.2337\/dc22-0833","volume":"45","author":"A Birukov","year":"2022","unstructured":"Birukov, A. et al. Immunoglobulin G N-glycosylation signatures in incident type 2 diabetes and cardiovascular disease. Diabetes Care 45, 2729\u20132736 (2022).","journal-title":"Diabetes Care"},{"key":"850_CR209","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.bbagen.2017.06.020","volume":"1861","author":"RFH Lemmers","year":"2017","unstructured":"Lemmers, R. F. H. et al. IgG glycan patterns are associated with type 2 diabetes in independent European populations. Biochim. Biophys. Acta Gen. Subj. 1861, 2240\u20132249 (2017).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"850_CR210","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001026","volume":"8","author":"SS Singh","year":"2020","unstructured":"Singh, S. S. et al. Association of the IgG N-glycome with the course of kidney function in type 2 diabetes. BMJ Open. Diabetes Res. Care 8, e001026 (2020).","journal-title":"BMJ Open. Diabetes Res. Care"},{"key":"850_CR211","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13098-023-01053-6","volume":"15","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Leveraging IgG N-glycosylation to infer the causality between T2D and hypertension. Diabetol. Metab. Syndr. 15, 80 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"850_CR212","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/1753-0407.13160","volume":"13","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Variation of IgG N-linked glycosylation profile in diabetic retinopathy. J. Diabetes 13, 672\u2013680 (2021).","journal-title":"J. Diabetes"},{"key":"850_CR213","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pnpbp.2013.08.014","volume":"48","author":"M Nikolac Perkovic","year":"2014","unstructured":"Nikolac Perkovic, M. et al. The association between galactosylation of immunoglobulin G and body mass index. Prog. Neuropsychopharmacol. Biol. Psychiatry 48, 20\u201325 (2014).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"850_CR214","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.imbio.2018.10.002","volume":"224","author":"AC Russell","year":"2019","unstructured":"Russell, A. C. et al. Increased central adiposity is associated with pro-inflammatory immunoglobulin G N-glycans. Immunobiology 224, 110\u2013115 (2019).","journal-title":"Immunobiology"},{"key":"850_CR215","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41366-021-00816-3","volume":"45","author":"VL Greto","year":"2021","unstructured":"Greto, V. L. et al. Extensive weight loss reduces glycan age by altering IgG N-glycosylation. Int. J. Obes. 45, 1521\u20131531 (2021).","journal-title":"Int. J. Obes."},{"key":"850_CR216","doi-asserted-by":"crossref","unstructured":"Kifer, D. et al. N-glycosylation of immunoglobulin G predicts incident hypertension. J. Hypertens. 39, 2527\u20132533 (2021).","DOI":"10.1097\/HJH.0000000000002963"},{"key":"850_CR217","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41371-018-0071-0","volume":"32","author":"JN Liu","year":"2018","unstructured":"Liu, J. N. et al. The association between subclass-specific IgG Fc N-glycosylation profiles and hypertension in the Uygur, Kazak, Kirgiz, and Tajik populations. J. Hum. Hypertens. 32, 555\u2013563 (2018).","journal-title":"J. Hum. Hypertens."},{"key":"850_CR218","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/jpm11070614","volume":"11","author":"X Meng","year":"2021","unstructured":"Meng, X. et al. Glycosylation of IgG associates with hypertension and type 2 diabetes mellitus comorbidity in the Chinese Muslim ethnic minorities and the Han Chinese. J. Pers. Med. 11, 614 (2021).","journal-title":"J. Pers. Med."},{"key":"850_CR219","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003379","volume":"95","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. The association between glycosylation of immunoglobulin G and hypertension: a multiple ethnic cross-sectional study. Medicine 95, e3379 (2016).","journal-title":"Medicine"},{"key":"850_CR220","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1616-2","volume":"16","author":"D Liu","year":"2018","unstructured":"Liu, D. et al. The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia. J. Transl. Med. 16, 235 (2018).","journal-title":"J. Transl. Med."},{"key":"850_CR221","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1161\/CIRCRESAHA.117.312174","volume":"122","author":"C Menni","year":"2018","unstructured":"Menni, C. et al. Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts. Circ. Res. 122, 1555\u20131564 (2018).","journal-title":"Circ. Res."},{"key":"850_CR222","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00125-022-05703-8","volume":"65","author":"N Rudman","year":"2022","unstructured":"Rudman, N. et al. Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG. Diabetologia 65, 1315\u20131327 (2022).","journal-title":"Diabetologia"},{"key":"850_CR223","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/glycob\/cwaa106","volume":"31","author":"M Colombo","year":"2021","unstructured":"Colombo, M. et al. Quantitative levels of serum N-glycans in type 1 diabetes and their association with kidney disease. Glycobiology 31, 613\u2013623 (2021).","journal-title":"Glycobiology"},{"key":"850_CR224","first-page":"149","volume":"81","author":"GA Rook","year":"1994","unstructured":"Rook, G. A. et al. A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. Immunology 81, 149\u2013154 (1994).","journal-title":"Immunology"},{"key":"850_CR225","doi-asserted-by":"publisher","first-page":"eabc8378","DOI":"10.1126\/science.abc8378","volume":"371","author":"MD Larsen","year":"2021","unstructured":"Larsen, M. D. et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science 371, eabc8378 (2021).","journal-title":"Science"},{"key":"850_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011223","volume":"19","author":"A Teo","year":"2023","unstructured":"Teo, A., Tan, H. D., Loy, T., Chia, P. Y. & Chua, C. L. L. Understanding antibody-dependent enhancement in dengue: are afucosylated IgG1s a concern? PLoS Pathog. 19, e1011223 (2023).","journal-title":"PLoS Pathog."},{"key":"850_CR227","doi-asserted-by":"publisher","first-page":"1188838","DOI":"10.3389\/fimmu.2023.1188838","volume":"14","author":"S Trzos","year":"2023","unstructured":"Trzos, S., Link-Lenczowski, P. & Poche\u0107, E. The role of N-glycosylation in B-cell biology and IgG activity. The aspects of autoimmunity and anti-inflammatory therapy. Front. Immunol. 14, 1188838 (2023).","journal-title":"Front. Immunol."},{"key":"850_CR228","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-017-1389-7","volume":"19","author":"SL Lundstr\u00f6m","year":"2017","unstructured":"Lundstr\u00f6m, S. L. et al. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. Arthritis Res. Ther. 19, 182 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"850_CR229","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/rheumatology\/ket189","volume":"52","author":"ES Collins","year":"2013","unstructured":"Collins, E. S. et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology 52, 1572\u20131582 (2013).","journal-title":"Rheumatology"},{"key":"850_CR230","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jcla.20191","volume":"21","author":"A Croce","year":"2007","unstructured":"Croce, A. et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J. Clin. Lab. Anal. 21, 303\u2013314 (2007).","journal-title":"J. Clin. Lab. Anal."},{"key":"850_CR231","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/ar3756","volume":"14","author":"A Ercan","year":"2012","unstructured":"Ercan, A. et al. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res. Ther. 14, R43 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"850_CR232","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s10020-019-0093-2","volume":"25","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis. Mol. Med. 25, 25 (2019).","journal-title":"Mol. Med."},{"key":"850_CR233","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3390\/biomedicines10081774","volume":"10","author":"G Font","year":"2022","unstructured":"Font, G. et al. IgG N-glycosylation from patients with pemphigus treated with rituximab. Biomedicines 10, 1774 (2022).","journal-title":"Biomedicines"},{"key":"850_CR234","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59651-7","volume":"10","author":"DE Schmidt","year":"2020","unstructured":"Schmidt, D. E. et al. IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia. Sci. Rep. 10, 3051 (2020).","journal-title":"Sci. Rep."},{"key":"850_CR235","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1681\/ASN.2015010109","volume":"27","author":"C Barrios","year":"2016","unstructured":"Barrios, C. et al. Glycosylation profile of IgG in moderate kidney dysfunction. J. Am. Soc. Nephrol. 27, 933\u2013941 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR236","doi-asserted-by":"publisher","first-page":"140453","DOI":"10.1172\/JCI140453","volume":"131","author":"Haddad","year":"2021","unstructured":"Haddad & G et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J. Clin. Invest. 131, 140453 (2021).","journal-title":"J. Clin. Invest."},{"key":"850_CR237","doi-asserted-by":"publisher","first-page":"1087532","DOI":"10.3389\/fimmu.2023.1087532","volume":"14","author":"N Oskam","year":"2023","unstructured":"Oskam, N. et al. Factors affecting IgG4-mediated complement activation. Front. Immunol. 14, 1087532 (2023).","journal-title":"Front. Immunol."},{"key":"850_CR238","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.3390\/ijms23094664","volume":"23","author":"C Chinello","year":"2022","unstructured":"Chinello, C. et al. Definition of IgG subclass-specific glycopatterns in idiopathic membranous nephropathy: aberrant IgG glycoforms in blood. Int. J. Mol. Sci. 23, 4664 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"850_CR239","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/ndt\/8.8.696","volume":"8","author":"M Segelmark","year":"1993","unstructured":"Segelmark, M. & Wieslander, J. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA). Nephrol. Dial. Transpl. 8, 696\u2013702 (1993).","journal-title":"Nephrol. Dial. Transpl."},{"key":"850_CR240","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/art.30362","volume":"63","author":"C Espy","year":"2011","unstructured":"Espy, C. et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener\u2019s). Arthritis Rheum. 63, 2105\u20132115 (2011).","journal-title":"Arthritis Rheum."},{"key":"850_CR241","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/S0021-9258(19)75677-4","volume":"262","author":"N Shibuya","year":"1987","unstructured":"Shibuya, N. et al. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(\u02512-6)Gal\/GalNAc sequence. J. Biol. Chem. 262, 1596\u20131601 (1987).","journal-title":"J. Biol. Chem."},{"key":"850_CR242","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1002\/pmic.200800931","volume":"9","author":"J Stadlmann","year":"2009","unstructured":"Stadlmann, J. et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 9, 4143\u20134153 (2009).","journal-title":"Proteomics"},{"key":"850_CR243","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1023\/A:1007183915921","volume":"16","author":"M Dalziel","year":"1999","unstructured":"Dalziel, M., McFarlane, I. & Axford, J. S. Lectin analysis of human immunoglobulin G N-glycan sialylation. Glycoconj. J. 16, 801\u2013807 (1999).","journal-title":"Glycoconj. J."},{"key":"850_CR244","first-page":"327","volume":"2","author":"TW Rademacher","year":"1991","unstructured":"Rademacher, T. W. Network theory of glycosylation \u2014 etiologic and pathogenic implications of changes in IgG glycoform levels in autoimmunity. Semin. Cell Biol. 2, 327\u2013337 (1991).","journal-title":"Semin. Cell Biol."},{"key":"850_CR245","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/cei.12744","volume":"184","author":"I Magorivska","year":"2016","unstructured":"Magorivska, I. et al. Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells. Clin. Exp. Immunol. 184, 110\u2013117 (2016).","journal-title":"Clin. Exp. Immunol."},{"key":"850_CR246","doi-asserted-by":"publisher","first-page":"102804","DOI":"10.1016\/j.autrev.2021.102804","volume":"20","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Antibody glycosylation in autoimmune diseases. Autoimmun. Rev. 20, 102804 (2021).","journal-title":"Autoimmun. Rev."},{"key":"850_CR247","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1177\/0961203316640368","volume":"25","author":"MHC Biermann","year":"2016","unstructured":"Biermann, M. H. C. et al. Sweet but dangerous \u2014 the role of immunoglobulin G glycosylation in autoimmunity and inflammation. Lupus 25, 934\u2013942 (2016).","journal-title":"Lupus"},{"key":"850_CR248","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1002\/art.39273","volume":"67","author":"F Vu\u010dkovi\u0107","year":"2015","unstructured":"Vu\u010dkovi\u0107, F. et al. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 67, 2978\u20132989 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"850_CR249","doi-asserted-by":"publisher","first-page":"103883","DOI":"10.1016\/j.ebiom.2022.103883","volume":"77","author":"J Han","year":"2022","unstructured":"Han, J. et al. Fucosylation of anti-dsDNA IgG1 correlates with disease activity of treatment-na\u00efve systemic lupus erythematosus patients. eBioMedicine 77, 103883 (2022).","journal-title":"eBioMedicine"},{"key":"850_CR250","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147789","volume":"6","author":"R Bhargava","year":"2021","unstructured":"Bhargava, R. et al. Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. JCI Insight 6, e147789 (2021).","journal-title":"JCI Insight"},{"key":"850_CR251","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41584-021-00626-x","volume":"17","author":"J Clarke","year":"2021","unstructured":"Clarke, J. Glycosylation influences IgG effects in LN. Nat. Rev. Rheumatol. 17, 310\u2013310 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"850_CR252","doi-asserted-by":"publisher","first-page":"1257906","DOI":"10.3389\/fimmu.2023.1257906","volume":"14","author":"X Lu","year":"2023","unstructured":"Lu, X. et al. Association between immunoglobulin G N-glycosylation and lupus nephritis in female patients with systemic lupus erythematosus: a case-control study. Front. Immunol. 14, 1257906 (2023).","journal-title":"Front. Immunol."},{"key":"850_CR253","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1471-4906(01)01873-7","volume":"22","author":"M van Egmond","year":"2001","unstructured":"van Egmond, M. et al. IgA and the IgA Fc receptor. Trends Immunol. 22, 205\u2013211 (2001).","journal-title":"Trends Immunol."},{"key":"850_CR254","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00281-012-0306-z","volume":"34","author":"J Novak","year":"2012","unstructured":"Novak, J., Julian, B. A., Mestecky, J. & Renfrow, M. B. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin. Immunopathol. 34, 365\u2013382 (2012).","journal-title":"Semin. Immunopathol."},{"key":"850_CR255","doi-asserted-by":"publisher","first-page":"974854","DOI":"10.3389\/fchem.2022.974854","volume":"10","author":"L Ding","year":"2022","unstructured":"Ding, L., Chen, X., Cheng, H., Zhang, T. & Li, Z. Advances in IgA glycosylation and its correlation with diseases. Front. Chem. 10, 974854 (2022).","journal-title":"Front. Chem."},{"key":"850_CR256","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.3390\/jcm10163467","volume":"10","author":"Y Ohyama","year":"2021","unstructured":"Ohyama, Y., Renfrow, M. B., Novak, J. & Takahashi, K. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don\u2019t know. J. Clin. Med. 10, 3467 (2021).","journal-title":"J. Clin. Med."},{"key":"850_CR257","doi-asserted-by":"publisher","first-page":"E8882","DOI":"10.1073\/pnas.1807478115","volume":"115","author":"MT Posgai","year":"2018","unstructured":"Posgai, M. T. et al. Fc\u03b1RI binding at the IgA1 CH2-CH3 interface induces long-range conformational changes that are transmitted to the hinge region. Proc. Natl Acad. Sci. USA 115, E8882\u2013E8891 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR258","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.semnephrol.2018.05.016","volume":"38","author":"J Novak","year":"2018","unstructured":"Novak, J., Barratt, J., Julian, B. A. & Renfrow, M. B. Aberrant glycosylation of the IgA1 Molecule in IgA nephropathy. Semin. Nephrol. 38, 461\u2013476 (2018).","journal-title":"Semin. Nephrol."},{"key":"850_CR259","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00281-021-00883-8","volume":"43","author":"H Suzuki","year":"2021","unstructured":"Suzuki, H. & Novak, J. IgA glycosylation and immune complex formation in IgAN. Semin. Immunopathol. 43, 669\u2013678 (2021).","journal-title":"Semin. Immunopathol."},{"key":"850_CR260","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","volume":"71","author":"Z Moldoveanu","year":"2007","unstructured":"Moldoveanu, Z. et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 71, 1148\u20131154 (2007).","journal-title":"Kidney Int."},{"key":"850_CR261","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2012010053","volume":"23","author":"F Berthoux","year":"2012","unstructured":"Berthoux, F. et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J. Am. Soc. Nephrol. 23, 1579\u20131587 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR262","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","volume":"82","author":"N Zhao","year":"2012","unstructured":"Zhao, N. et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 82, 790\u2013796 (2012).","journal-title":"Kidney Int."},{"key":"850_CR263","first-page":"1668","volume":"119","author":"H Suzuki","year":"2009","unstructured":"Suzuki, H. et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119, 1668\u20131677 (2009).","journal-title":"J. Clin. Invest."},{"key":"850_CR264","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut, P., Avila-Casado, C. & Reich, H. N. IgA nephropathy: core curriculum 2021. Am. J. Kidney Dis. 78, 429\u2013441 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"850_CR265","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/jcm10194501","volume":"10","author":"B Knoppova","year":"2021","unstructured":"Knoppova, B. et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment. J. Clin. Med. 10, 4501 (2021).","journal-title":"J. Clin. Med."},{"key":"850_CR266","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.2215\/CJN.01300121","volume":"16","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Poly-IgA complexes and disease severity in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 16, 1652\u20131664 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"850_CR267","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190967","volume":"13","author":"WJ Placzek","year":"2018","unstructured":"Placzek, W. J. et al. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS One 13, e0190967 (2018).","journal-title":"PLoS One"},{"key":"850_CR268","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212254","volume":"14","author":"D Maixnerova","year":"2019","unstructured":"Maixnerova, D. et al. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PLoS One 14, e0212254 (2019).","journal-title":"PLoS One"},{"key":"850_CR269","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ndt\/gfaa356","volume":"37","author":"AS Medrano","year":"2022","unstructured":"Medrano, A. S. et al. Relationship between immunoglobulin A1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in immunoglobulin A nephropathy. Nephrol. Dial. Transpl. 37, 318\u2013325 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"850_CR270","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.2215\/CJN.13711118","volume":"14","author":"P Chen","year":"2019","unstructured":"Chen, P. et al. Plasma galactose-deficient IgA1 and C3 and CKD progression in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 14, 1458\u20131465 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"850_CR271","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1159\/000430151","volume":"36","author":"Y Liang","year":"2015","unstructured":"Liang, Y. et al. Proliferation and cytokine production of human mesangial cells stimulated by secretory IgA isolated from patients with IgA nephropathy. Cell Physiol. Biochem. 36, 1793\u20131808 (2015).","journal-title":"Cell Physiol. Biochem."},{"key":"850_CR272","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000514183","volume":"46","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Role of human mesangial-tubular crosstalk in secretory IgA-induced IgA nephropathy. Kidney Blood Press. Res. 46, 286\u2013297 (2021).","journal-title":"Kidney Blood Press. Res."},{"key":"850_CR273","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1053\/ajkd.2000.19840","volume":"36","author":"A Amore","year":"2000","unstructured":"Amore, A. et al. Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am. J. Kidney Dis. 36, 1242\u20131252 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"850_CR274","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/jir.2022.0039","volume":"42","author":"T Person","year":"2022","unstructured":"Person, T. et al. Cytokines and production of aberrantly O-glycosylated IgA1, the main autoantigen in IgA nephropathy. J. Interferon Cytokine Res. 42, 301\u2013315 (2022).","journal-title":"J. Interferon Cytokine Res."},{"key":"850_CR275","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40620-015-0246-5","volume":"29","author":"SM Lechner","year":"2016","unstructured":"Lechner, S. M., Papista, C., Chemouny, J. M., Berthelot, L. & Monteiro, R. C. Role of IgA receptors in the pathogenesis of IgA nephropathy. J. Nephrol. 29, 5\u201311 (2016).","journal-title":"J. Nephrol."},{"key":"850_CR276","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.trsl.2020.10.007","volume":"230","author":"JH Jhee","year":"2021","unstructured":"Jhee, J. H. et al. CD71 mesangial IgA1 receptor and the progression of IgA nephropathy. Transl. Res. 230, 34\u201343 (2021).","journal-title":"Transl. Res."},{"key":"850_CR277","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.kint.2021.09.023","volume":"101","author":"A Cambier","year":"2022","unstructured":"Cambier, A. et al. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy. Kidney Int. 101, 274\u2013287 (2022).","journal-title":"Kidney Int."},{"key":"850_CR278","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt, R. J. & Julian, B. A. IgA nephropathy. N. Engl. J. Med. 368, 2402\u20132414 (2013).","journal-title":"N. Engl. J. Med."},{"key":"850_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13992-8","volume":"11","author":"U Steffen","year":"2020","unstructured":"Steffen, U. et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat. Commun. 11, 120 (2020).","journal-title":"Nat. Commun."},{"key":"850_CR280","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188718","volume":"12","author":"E Pillebout","year":"2017","unstructured":"Pillebout, E. et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One 12, e0188718 (2017).","journal-title":"PLoS One"},{"key":"850_CR281","doi-asserted-by":"publisher","first-page":"771619","DOI":"10.3389\/fimmu.2021.771619","volume":"12","author":"Y Song","year":"2021","unstructured":"Song, Y. et al. Pathogenesis of IgA vasculitis: an up-to-date review. Front. Immunol. 12, 771619 (2021).","journal-title":"Front. Immunol."},{"key":"850_CR282","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232194","volume":"15","author":"M Sugiyama","year":"2020","unstructured":"Sugiyama, M. et al. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Sch\u00f6nlein purpura nephritis and IgA nephropathy. PLoS One 15, e0232194 (2020).","journal-title":"PLoS One"},{"key":"850_CR283","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00281-021-00893-6","volume":"43","author":"K Haniuda","year":"2021","unstructured":"Haniuda, K., Gommerman, J. L. & Reich, H. N. The microbiome and IgA nephropathy. Semin. Immunopathol. 43, 649\u2013656 (2021).","journal-title":"Semin. Immunopathol."},{"key":"850_CR284","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semnephrol.2007.10.009","volume":"28","author":"J Novak","year":"2008","unstructured":"Novak, J., Julian, B. A., Tomana, M. & Mestecky, J. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin. Nephrol. 28, 78\u201387 (2008).","journal-title":"Semin. Nephrol."},{"key":"850_CR285","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1681\/ASN.2006060658","volume":"17","author":"AC Smith","year":"2006","unstructured":"Smith, A. C., Molyneux, K., Feehally, J. & Barratt, J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J. Am. Soc. Nephrol. 17, 3520\u20133528 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR286","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1681\/ASN.2016091043","volume":"28","author":"DP Gale","year":"2017","unstructured":"Gale, D. P. et al. Galactosylation of IgA1 is associated with common variation in C1GALT1. J. Am. Soc. Nephrol. 28, 2158\u20132166 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR287","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-019-1675-5","volume":"21","author":"Y Xing","year":"2020","unstructured":"Xing, Y. et al. C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy. BMC Nephrol. 21, 18 (2020).","journal-title":"BMC Nephrol."},{"key":"850_CR288","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellar\u00e9s","year":"2012","unstructured":"Sellar\u00e9s, J. et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am. J. Transplant. 12, 388\u2013399 (2012).","journal-title":"Am. J. Transplant."},{"key":"850_CR289","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","volume":"102","author":"C Roufosse","year":"2018","unstructured":"Roufosse, C. et al. A 2018 reference guide to the Banff Classification of Renal Allograft Pathology. Transplantation 102, 1795\u20131814 (2018).","journal-title":"Transplantation"},{"key":"850_CR290","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","volume":"18","author":"M Haas","year":"2018","unstructured":"Haas, M. et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am. J. Transplant. 18, 293\u2013307 (2018).","journal-title":"Am. J. Transplant."},{"key":"850_CR291","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrneph.2012.81","volume":"8","author":"A Loupy","year":"2012","unstructured":"Loupy, A., Hill, G. S. & Jordan, S. C. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat. Rev. Nephrol. 8, 348\u2013357 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"850_CR292","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/ASN.2009101065","volume":"21","author":"C Lefaucheur","year":"2010","unstructured":"Lefaucheur, C. et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21, 1398\u20131406 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR293","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/01.TP.0000441362.11232.48","volume":"97","author":"MJ Everly","year":"2014","unstructured":"Everly, M. J. et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 97, 494\u2013501 (2014).","journal-title":"Transplantation"},{"key":"850_CR294","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13219","volume":"22","author":"G Hamdani","year":"2018","unstructured":"Hamdani, G. et al. IGG3 anti-HLA donor-specific antibodies and graft function in pediatric kidney transplant recipients. Pediatr. Transpl. 22, e13219 (2018).","journal-title":"Pediatr. Transpl."},{"key":"850_CR295","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1681\/ASN.2014111120","volume":"27","author":"C Lefaucheur","year":"2016","unstructured":"Lefaucheur, C. et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J. Am. Soc. Nephrol. 27, 293\u2013304 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR296","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/ajt.16904","volume":"22","author":"V Pernin","year":"2022","unstructured":"Pernin, V. et al. IgG3 donor-specific antibodies with a proinflammatory glycosylation profile may be associated with the risk of antibody-mediated rejection after kidney transplantation. Am. J. Transpl. 22, 865\u2013875 (2022).","journal-title":"Am. J. Transpl."},{"key":"850_CR297","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3389\/fimmu.2020.00919","volume":"11","author":"V Pernin","year":"2020","unstructured":"Pernin, V. et al. Distribution of de novo donor-specific antibody subclasses quantified by mass spectrometry: high IgG3 proportion is associated with antibody-mediated rejection occurrence and severity. Front. Immunol. 11, 919 (2020).","journal-title":"Front. Immunol."},{"key":"850_CR298","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/TP.0000000000001816","volume":"102","author":"NM Valenzuela","year":"2018","unstructured":"Valenzuela, N. M. & Schaub, S. The biology of IgG subclasses and their clinical relevance to transplantation. Transplantation 102, S7\u2013S13 (2018).","journal-title":"Transplantation"},{"key":"850_CR299","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.2016030368","volume":"28","author":"D Viglietti","year":"2017","unstructured":"Viglietti, D. et al. Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J. Am. Soc. Nephrol. 28, 702\u2013715 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR300","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/ajt.14161","volume":"17","author":"CA Schinstock","year":"2017","unstructured":"Schinstock, C. A. et al. The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss. Am. J. Transpl. 17, 1574\u20131584 (2017).","journal-title":"Am. J. Transpl."},{"key":"850_CR301","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/TP.0000000000002002","volume":"102","author":"E Bailly","year":"2018","unstructured":"Bailly, E. et al. Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation. Transplantation 102, 688\u2013698 (2018).","journal-title":"Transplantation"},{"key":"850_CR302","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trim.2018.03.002","volume":"49","author":"HB Cazarote","year":"2018","unstructured":"Cazarote, H. B. et al. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure. Transpl. Immunol. 49, 33\u201338 (2018).","journal-title":"Transpl. Immunol."},{"key":"850_CR303","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","volume":"369","author":"A Loupy","year":"2013","unstructured":"Loupy, A. et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 369, 1215\u20131226 (2013).","journal-title":"N. Engl. J. Med."},{"key":"850_CR304","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/TP.0000000000002265","volume":"102","author":"J Malheiro","year":"2018","unstructured":"Malheiro, J. et al. Detection of complement-binding donor-specific antibodies, not IgG-antibody strength nor C4d status, at antibody-mediated rejection diagnosis is an independent predictor of kidney graft failure. Transplantation 102, 1943\u20131954 (2018).","journal-title":"Transplantation"},{"key":"850_CR305","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1681\/ASN.2013101144","volume":"26","author":"A Sicard","year":"2015","unstructured":"Sicard, A. et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J. Am. Soc. Nephrol. 26, 457\u2013467 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"850_CR306","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.transproceed.2013.11.011","volume":"46","author":"D Thammanichanond","year":"2014","unstructured":"Thammanichanond, D. et al. Significance of C1q-fixing donor-specific antibodies after kidney transplantation. Transpl. Proc. 46, 368\u2013371 (2014).","journal-title":"Transpl. Proc."},{"key":"850_CR307","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.transproceed.2015.12.116","volume":"48","author":"D Thammanichanond","year":"2016","unstructured":"Thammanichanond, D. et al. Role of pretransplant complement-fixing donor-specific antibodies identified by C1q assay in kidney transplantation. Transpl. Proc. 48, 756\u2013760 (2016).","journal-title":"Transpl. Proc."},{"key":"850_CR308","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.kint.2018.03.015","volume":"94","author":"D Viglietti","year":"2018","unstructured":"Viglietti, D. et al. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int. 94, 773\u2013787 (2018).","journal-title":"Kidney Int."},{"key":"850_CR309","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.humimm.2015.10.021","volume":"77","author":"S Malard-Castagnet","year":"2016","unstructured":"Malard-Castagnet, S. et al. Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection. Hum. Immunol. 77, 1076\u20131083 (2016).","journal-title":"Hum. Immunol."},{"key":"850_CR310","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3389\/fimmu.2019.00513","volume":"10","author":"T Barba","year":"2019","unstructured":"Barba, T. et al. Highly variable sialylation status of donor-specific antibodies does not impact humoral rejection outcomes. Front. Immunol. 10, 513 (2019).","journal-title":"Front. Immunol."},{"key":"850_CR311","doi-asserted-by":"publisher","first-page":"100818","DOI":"10.1016\/j.xcrm.2022.100818","volume":"3","author":"P Bharadwaj","year":"2022","unstructured":"Bharadwaj, P. et al. Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation. Cell Rep. Med. 3, 100818 (2022).","journal-title":"Cell Rep. Med."},{"key":"850_CR312","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ajt.16140","volume":"21","author":"R Bhargava","year":"2021","unstructured":"Bhargava, R. et al. N-glycosylated IgG in patients with kidney transplants increases calcium\/calmodulin kinase IV in podocytes and causes injury. Am. J. Transpl. 21, 148\u2013160 (2021).","journal-title":"Am. J. Transpl."},{"key":"850_CR313","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2007-8-11-r254","volume":"8","author":"DJ Schofield","year":"2007","unstructured":"Schofield, D. J. et al. Application of phage display to high throughput antibody generation and characterization. Genome Biol. 8, R254 (2007).","journal-title":"Genome Biol."},{"key":"850_CR314","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.1021\/acs.chemrev.1c00380","volume":"122","author":"M Grabarics","year":"2022","unstructured":"Grabarics, M. et al. Mass spectrometry-based techniques to elucidate the sugar code. Chem. Rev. 122, 7840\u20137908 (2022).","journal-title":"Chem. Rev."},{"key":"850_CR315","doi-asserted-by":"publisher","first-page":"108201","DOI":"10.1016\/j.biotechadv.2023.108201","volume":"67","author":"M Garc\u00eda-Alija","year":"2023","unstructured":"Garc\u00eda-Alija, M. et al. Modulating antibody effector functions by Fc glycoengineering. Biotechnol. Adv. 67, 108201 (2023).","journal-title":"Biotechnol. Adv."},{"key":"850_CR316","doi-asserted-by":"publisher","first-page":"929895","DOI":"10.3389\/fimmu.2022.929895","volume":"13","author":"J Golay","year":"2022","unstructured":"Golay, J., Andrea, A. E. & Cattaneo, I. Role of Fc core fucosylation in the effector function of IgG1 antibodies. Front. Immunol. 13, 929895 (2022).","journal-title":"Front. Immunol."},{"key":"850_CR317","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner, E. et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115, 4393\u20134402 (2010).","journal-title":"Blood"},{"key":"850_CR318","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ckj\/sfab250","volume":"15","author":"NE Ginth\u00f6r","year":"2022","unstructured":"Ginth\u00f6r, N. E., Artinger, K., Pollheimer, M. J., Stradner, M. H. & Eller, K. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. Clin. Kidney J. 15, 564\u2013566 (2022).","journal-title":"Clin. Kidney J."},{"key":"850_CR319","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","volume":"23","author":"R Hudson","year":"2022","unstructured":"Hudson, R., Rawlings, C., Mon, S. Y., Jefferis, J. & John, G. T. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases. BMC Nephrol. 23, 134 (2022).","journal-title":"BMC Nephrol."},{"key":"850_CR320","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ekir.2023.01.035","volume":"8","author":"S Naik","year":"2023","unstructured":"Naik, S. et al. Obinutuzumab in refractory phospholipase A2 receptor-associated membranous nephropathy with severe CKD. Kidney Int. Rep. 8, 942\u2013943 (2023).","journal-title":"Kidney Int. Rep."},{"key":"850_CR321","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1073\/pnas.1402458111","volume":"111","author":"A Hiatt","year":"2014","unstructured":"Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl Acad. Sci. USA 111, 5992\u20135997 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR322","doi-asserted-by":"publisher","first-page":"e00937","DOI":"10.1128\/JVI.00937-17","volume":"91","author":"A Bardhi","year":"2017","unstructured":"Bardhi, A. et al. Potent in vivo NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein. J. Virol. 91, e00937\u201317 (2017).","journal-title":"J. Virol."},{"key":"850_CR323","doi-asserted-by":"publisher","first-page":"20690","DOI":"10.1073\/pnas.1108360108","volume":"108","author":"L Zeitlin","year":"2011","unstructured":"Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl Acad. Sci. USA 108, 20690\u201320694 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"850_CR324","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/glycob\/cwm017","volume":"17","author":"AJS Jones","year":"2007","unstructured":"Jones, A. J. S. et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17, 529\u2013540 (2007).","journal-title":"Glycobiology"},{"key":"850_CR325","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85329-9","volume":"11","author":"M Li","year":"2021","unstructured":"Li, M. et al. Next generation of anti-PD-L1 atezolizumab with enhanced anti-tumor efficacy in vivo. Sci. Rep. 11, 5774 (2021).","journal-title":"Sci. Rep."},{"key":"850_CR326","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ab.2007.01.023","volume":"364","author":"J Qian","year":"2007","unstructured":"Qian, J. et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption\/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem. 364, 8\u201318 (2007).","journal-title":"Anal. Biochem."},{"key":"850_CR327","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-62703-327-5_7","volume":"988","author":"M-C Janin-Bussat","year":"2013","unstructured":"Janin-Bussat, M.-C. et al. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol. Biol. 988, 93\u2013113 (2013).","journal-title":"Methods Mol. Biol."},{"key":"850_CR328","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung, C. H. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-\u0251-1,3-galactose. N. Engl. J. Med. 358, 1109\u20131117 (2008).","journal-title":"N. Engl. J. Med."},{"key":"850_CR329","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jaci.2014.12.1947","volume":"135","author":"JW Steinke","year":"2015","unstructured":"Steinke, J. W., Platts-Mills, T. A. E. & Commins, S. P. The alpha-gal story: lessons learned from connecting the dots. J. Allergy Clin. Immunol. 135, 589\u2013596 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"850_CR330","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.11.041","volume":"172","author":"JD Pagan","year":"2018","unstructured":"Pagan, J. D., Kitaoka, M. & Anthony, R. M. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell 172, 564\u2013577.e13 (2018).","journal-title":"Cell"},{"key":"850_CR331","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jaci.2012.02.037","volume":"129","author":"CM Oefner","year":"2012","unstructured":"Oefner, C. M. et al. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 129, 1647\u20131655.e13 (2012).","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00850-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T08:04:24Z","timestamp":1726128264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00850-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":331,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1038\/s41581-024-00850-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"20 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}